The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Imipenem/Cilastatin 250 mg/250 mg powder for solution for infusion



Fresenius Kabi Deutschland GmbHPA2059/074/001

Main Information

Trade NameImipenem/Cilastatin 250 mg/250 mg powder for solution for infusion
Active SubstancesImipenem
Cilastatin
Dosage FormPowder for solution for infusion
Licence HolderFresenius Kabi Deutschland GmbH
Licence NumberPA2059/074/001

Group Information

ATC CodeJ01DH51 imipenem and enzyme inhibitor

Status

License statusAuthorised
Licence Issued18/12/2020
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back